EMERALD: Switch From Boosted PI Plus FTC/TDF to DRV/COBI/FTC/TAF Single-Tablet Regimen Yields Favorable Efficacy and Safety at Interim Analysis
Conference Capsule - The single-tablet regimen demonstrated a low cumulative rate of virologic rebound through 24 weeks, with few serious AEs and discontinuations due to AEs. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 26, 2017 Category: Infectious Diseases Source Type: research
LATTE-2: Virologic Efficacy of Long-Acting Injectable Cabotegravir Plus Rilpivirine Comparable to Oral Cabotegravir-Based ART as Maintenance Therapy Through 96 Weeks in Treatment-Naive Patients
Conference Capsule - Encouraging long-term safety and efficacy data continue to support late-stage clinical development of long-acting injectable maintenance regimen. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 26, 2017 Category: Infectious Diseases Source Type: research
GS-1489: Bictegravir/FTC/TAF Noninferior to Dolutegravir/ABC/3TC in ART-Naive Patients at Week 48 in Phase III Trial
Conference Capsule - Novel unboosted INSTI-based regimen generally well tolerated with no emergent resistance mutations. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 25, 2017 Category: Infectious Diseases Source Type: research
ACTG A5353 Pilot Study: Dual Therapy With Dolutegravir Plus Lamivudine Efficacious, Safe in Treatment-Naive Patients Through Week 24
Conference Capsule - The 2-drug regimen yielded 90% virologic success at Week 24 in patients with baseline HIV-1 RNA up to 500,000 copies/mL. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 25, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: Managing ART in HIV-Infected Patients With Common Comorbidities
Slideset - In this downloadable slideset, David A. Wohl, MD, and Program Director Joseph J. Eron, Jr., MD, review key data and offer expert guidance on managing HIV treatment in patients with frequently encountered comorbidities, including cardiovascular disease, osteopenia, and HCV coinfection. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 19, 2017 Category: Infectious Diseases Source Type: research
IAS 2017: A Preview of Key Data to Be Presented in Paris
Discussion - Here is my take on the most anticipated studies that will be presented in Paris this year. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 17, 2017 Category: Infectious Diseases Source Type: research
Slideset
- (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 29, 2017 Category: Infectious Diseases Source Type: research
Weighing Boosted vs Unboosted Options for a Patient Who Requires Treatment Prior to Availability of Resistance Data
Discussion - For a newly-diagnosed patient with an OI and pending resistance test results, when and with what would you recommend initiating ART? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 21, 2017 Category: Infectious Diseases Source Type: research
Optimizing ART for a Patient With PI Intolerance and a History of Resistance and Nonadherence
Discussion - Would you switch a virologically suppressed patient who is experiencing PI toxicity to a PI-sparing regimen if they had history of nonadherence and resistance? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 21, 2017 Category: Infectious Diseases Source Type: research
Weighing Boosted vs Unboosted Options for a Patient With Comorbidities Who Desires an STR
Discussion - What is the optimal ART regimen for a patient with CKD and CVD who desires an STR? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 21, 2017 Category: Infectious Diseases Source Type: research
Contemporary Management of HIV: To Boost or Not to Boost: Advantages and Disadvantages of Boosted ART
Slideset - In this downloadable slideset, Eric S. Daar, MD, and Program Director Joseph J. Eron, Jr., MD, review advantages and disadvantages of boosted ART regimens for managing patients with HIV. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 16, 2017 Category: Infectious Diseases Source Type: research
Choosing Statins for Patients With Dyslipidemia and Elevated CVD Risk
Discussion - Which statins should be avoided in patients receiving boosted ART regimens? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - June 1, 2017 Category: Infectious Diseases Source Type: research
Selecting ART for an Aging Patient With Multiple Comorbidities and Potential Drug –Drug Interactions
Discussion - In an older patient managing hypertension, reactive airways disease, and moderate renal insufficiency, what ART regimen would you recommend? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - May 31, 2017 Category: Infectious Diseases Source Type: research
Adopting Lung Cancer Screening Recommendations for an HIV-Infected Individual With a Smoking History
Discussion - What qualifies an HIV-infected past or current smoker for annual lung cancer screening using low-dose CT scans? (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - May 31, 2017 Category: Infectious Diseases Source Type: research
ClinicalThought2
Discussion - (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - May 20, 2017 Category: Infectious Diseases Source Type: research
